Stada Prepares for Imminent IPO, Valuation Expected to Reach €10-12bn
PorAinvest
lunes, 17 de marzo de 2025, 7:36 am ET1 min de lectura
AG--
If successful, Stada would join the MDax or DAX index, two prestigious German stock market indices [2]. The company is majority-owned by private equity firms Bain Capital and Cinven, who are seeking to bolster Stada's pipeline ahead of the sale [1].
According to sources familiar with the matter, Barclays Plc, Citigroup Inc., HSBC Holdings Plc, Jefferies Financial Group Inc., and UBS Group AG have been selected as the bookrunners for the potential IPO [1]. Deutsche Bank AG and Goldman Sachs Group Inc. have also been added as global coordinators [1].
The decision to pursue an IPO comes after negotiations over a potential sale of Stada to rival investment firm GTCR cooled [1]. Stada's private equity owners, Bain Capital and Cinven, have been encouraged by the recent market rally and are considering filing the intention to float document early next year [1].
An IPO of Stada would rank as one of the biggest health-care transactions in Europe in recent years [1]. This move comes as a growing number of German firms gear up to go public despite concerns over Europe's largest economy [3].
Sources:
[1] + https://www.bnnbloomberg.ca/business/2024/11/08/stada-picks-ipo-bookrunners-eyes-kickoff-early-next-year/
[2] + https://www.frankfurt-stock-exchange.de/en/market-data/market-data-equities/german-stock-market-indices/
[3] + https://www.reuters.com/business/eu/german-companies-gear-up-ipos-amid-economic-uncertainty-2021-11-05/
BCS--
BCSF--
C--
Stada, a German drug manufacturer, is preparing for an imminent IPO. The announcement could be made as early as Wednesday, with a potential valuation of €10-12 billion. The company, majority-owned by Bain Capital and Cinven, aims to raise around €1.5 billion from the sale of shares. If the IPO is successful, Stada could join the MDax or DAX index.
Stada Arzneimittel AG, a German drug manufacturer with a consumer health-focused pipeline, is reportedly preparing for an initial public offering (IPO) [1]. The highly anticipated announcement could be made as early as Wednesday, with a potential valuation of €10-12 billion [1]. This potential listing would allow the company to raise approximately €1.5 billion from the sale of shares [1].If successful, Stada would join the MDax or DAX index, two prestigious German stock market indices [2]. The company is majority-owned by private equity firms Bain Capital and Cinven, who are seeking to bolster Stada's pipeline ahead of the sale [1].
According to sources familiar with the matter, Barclays Plc, Citigroup Inc., HSBC Holdings Plc, Jefferies Financial Group Inc., and UBS Group AG have been selected as the bookrunners for the potential IPO [1]. Deutsche Bank AG and Goldman Sachs Group Inc. have also been added as global coordinators [1].
The decision to pursue an IPO comes after negotiations over a potential sale of Stada to rival investment firm GTCR cooled [1]. Stada's private equity owners, Bain Capital and Cinven, have been encouraged by the recent market rally and are considering filing the intention to float document early next year [1].
An IPO of Stada would rank as one of the biggest health-care transactions in Europe in recent years [1]. This move comes as a growing number of German firms gear up to go public despite concerns over Europe's largest economy [3].
Sources:
[1] + https://www.bnnbloomberg.ca/business/2024/11/08/stada-picks-ipo-bookrunners-eyes-kickoff-early-next-year/
[2] + https://www.frankfurt-stock-exchange.de/en/market-data/market-data-equities/german-stock-market-indices/
[3] + https://www.reuters.com/business/eu/german-companies-gear-up-ipos-amid-economic-uncertainty-2021-11-05/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios